REG - Creo Medical Group - Result of Retail Offer

Creo MedicalAnnouncement

17/10/2024 17:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241017:nRSQ6704Ia&default-theme=true

RNS Number : 6704I  Creo Medical Group PLC  17 October 2024

THIS ANNOUNCEMENT, INCLUDING THE INFORMATION CONTAINED IN IT, IS RESTRICTED
AND IS NOT FOR RELEASE, PUBLICATION, DISTRIBUTION OR FORWARDING, IN WHOLE OR
IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, NEW
ZEALAND, CANADA, THE REPUBLIC OF IRELAND, THE REPUBLIC OF SOUTH AFRICA, JAPAN
OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION
WOULD BE UNLAWFUL.

 

FURTHER, THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND IS NOT AN
OFFER OF SECURITIES IN ANY JURISDICTION.

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION.

 

LEI: 213800H188ZDCWWXFA21

17 October 2024

Creo Medical Group plc

("Creo" or the "Company")

 

Result of Retail Offer

 

Further to the announcements dated 30 September 2024 and 4 October 2024 in
relation to the Retail Offer, Creo announces that, following the closing of
the Retail Offer by BookBuild earlier today, 369,109 Retail Offer Shares will
be issued at an Issue Price of 24 pence per Retail Offer Share in connection
with the Retail Offer.

 

Consequently, a total of 50,369,109 New Ordinary Shares, comprising 50,000,000
Placing Shares and 369,109 Retail Offer Shares will be issued conditional on
the passing of the Resolutions by Shareholders at the General Meeting to be
held on 18 October 2024.

 

Admission, settlement and dealings

 

Application will be made to the London Stock Exchange for the New Ordinary
Shares to be admitted to trading on AIM. Admission is expected to take place
at 8:00 a.m. on 21 October 2024 and dealings in the New Ordinary Shares are
expected to commence at 8.00 a.m. on 21 October 2024 or such later time and/or
date as the Joint Bookrunners and the Company agree (being in any event no
later than 8.00 a.m. on 11 November 2024).

 

The New Ordinary Shares, when issued, will be credited as fully paid and will
rank pari passu in all respects with the existing Ordinary Shares, including
the right to receive all dividends and other distributions declared, made or
paid after the date of issue.

 

Capitalised terms used but not defined in this announcement have the same
meanings as set out in the circular to Shareholders dated 1 October 2024.

 

For further information please contact:

 

 Creo Medical Group plc                                   www.creomedical.com (http://www.creomedical.com/)
 Richard Craven, Company Secretary                        Via Walbrook PR

 Cavendish Capital Markets Limited

 (Nominated Adviser, Joint Bookrunner and Joint Broker)   +44 (0)20 7220 0500
 Stephen Keys / Camilla Hume / George Lawson (NOMAD)
 Michael Johnson (Sales)

 Deutsche Numis (Joint Bookrunner and Joint Broker)       +44 (0)20 7260 1000

 Freddie Barnfield / Duncan Monteith / Euan Brown

 William Baunton (ECM)

 Walbrook PR Ltd                                          Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com (mailto:creo@walbrookpr.com)
 Paul McManus / Alice Woodings                            Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

About Creo Medical

 

Creo Medical is a medical device company focused on the development and
commercialisation of minimally invasive electrosurgical devices, bringing
advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development
and commercialisation of a suite of electrosurgical medical devices, each
enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA
powered by Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection, coagulation
and ablation of tissue. Kamaptive technology provides clinicians with
increased flexibility, precision and controlled surgical solutions. CROMA
currently delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for controlled
coagulation and ablation via a single accessory port. This technology,
combined with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and controlled clinical
solutions. The Directors believe the Company's technology can impact the
landscape of surgery and endoscopy by providing a safer, less-invasive and
more cost-efficient option for procedures.

 

For more information, please refer to the website www.creomedical.com
(http://www.creomedical.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  FURMRBFTMTTBBPI